| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | J. J. Rinehart | |
| P. L. Triozzi | |||
| P. Kinney | |||
| P2860 | cites work | Cancer Research | Q326097 |
| Clinical toxicity of interferons in cancer patients: a review | Q33411253 | ||
| Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism | Q33450431 | ||
| A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients | Q33451539 | ||
| Neurological effects of recombinant human interferon | Q34990158 | ||
| Recombinant interferon in advanced breast cancer | Q35991406 | ||
| Tumor necrosis factor: still a promising agent | Q38603549 | ||
| NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. | Q39641278 | ||
| Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer | Q40777027 | ||
| Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic Study | Q40783265 | ||
| Phase I study of multiple dose intramuscularly administered recombinant gamma interferon | Q40807037 | ||
| Sleep-promoting effects of endogenous pyrogen (interleukin-1). | Q40826714 | ||
| Central nervous system toxicity of interferon | Q41507160 | ||
| Interferon enhances the excitability of cultured neurones | Q41515271 | ||
| Neurologic sequelae following interferon therapy of juvenile laryngeal papilloma | Q43525754 | ||
| Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity | Q44352623 | ||
| Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines | Q47584438 | ||
| Interleukin-1 immunoreactive innervation of the human hypothalamus | Q48088092 | ||
| Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers | Q48474423 | ||
| Effects of interferon alpha on performance in man: a preliminary report. | Q50801563 | ||
| Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. | Q51230896 | ||
| Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. | Q52072984 | ||
| The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. | Q52073727 | ||
| The determination of an immunologically active dose of interferon-gamma in patients with melanoma | Q70382013 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | history and philosophy of science | Q5774812 |
| P304 | page(s) | 347-354 | |
| P577 | publication date | 1990-01-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Central nervous system toxicity of biological response modifiers | |
| Central Nervous System Toxicity of Biological Response Modifiers | |||
| P478 | volume | 594 |
| Q33328717 | Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1 |
| Q33729899 | Neuropsychiatric toxicity associated with cytokine therapies |
| Q44599530 | The receptor for tumor necrosis factor on murine astrocytes: characterization, intracellular degradation, and regulation by cytokines and Theiler's murine encephalomyelitis virus. |
Search more.